Adam D Cohen, MD Profile
Adam D Cohen, MD

@CohenAd_MMdoc

Followers
525
Following
4
Statuses
31

Myeloma Amyloidosis Immunotherapy

Joined November 2013
Don't wanna be here? Send us removal request.
@CohenAd_MMdoc
Adam D Cohen, MD
@CohenAd_MMdoc
9 years
@SandyWong02111 @brendanweiss anyone know if the European VMD vs. MD trial stratified by cytogenetics? #amyloidosisjc
2
0
0
@CohenAd_MMdoc
Adam D Cohen, MD
@CohenAd_MMdoc
9 years
Intriguing data but small numbers overall. Mayo group couldn't confirm findings in their series. #amyloidosisjc
2
1
5
@CohenAd_MMdoc
Adam D Cohen, MD
@CohenAd_MMdoc
9 years
Hi everyone. About 60% had t(11;14). is this representative of what you are generally finding in your practices? #amyloidosisJC
3
0
3
@CohenAd_MMdoc
Adam D Cohen, MD
@CohenAd_MMdoc
9 years
Royal pumpkins @woodloch
0
0
1
@CohenAd_MMdoc
Adam D Cohen, MD
@CohenAd_MMdoc
9 years
@brendanweiss @PennCancer - typo alert: Carfilzomib MTD actually 20/36 in rel/ref AL. #mmsm
1
1
2
@CohenAd_MMdoc
Adam D Cohen, MD
@CohenAd_MMdoc
10 years
Thanks everyone!! #mmsm
1
0
1
@CohenAd_MMdoc
Adam D Cohen, MD
@CohenAd_MMdoc
10 years
@myelomacinderel @mtmdphd Depends on target, but haven't seen increased infections with chkpt inhibitors or Elo #mmsm
1
2
2
@CohenAd_MMdoc
Adam D Cohen, MD
@CohenAd_MMdoc
10 years
@NorthTxMSG agreed. may need combinations of approaches - mAbs, vaccines, cellular therapy to eradicate disease #mmsm
0
1
2
@CohenAd_MMdoc
Adam D Cohen, MD
@CohenAd_MMdoc
10 years
@mtmdphd yes multiple vaccine targets in development - idiotype, MAGE-A3, CS1, XBP1. Also dendritic cell-myeloma cell fusions. #mmsm
0
1
2
@CohenAd_MMdoc
Adam D Cohen, MD
@CohenAd_MMdoc
10 years
#mmsm T4 Active vaccination aims to induce patient’s own immune system to attack myeloma cells
0
1
2
@CohenAd_MMdoc
Adam D Cohen, MD
@CohenAd_MMdoc
10 years
@MyelomaTeacher yes, that's been seen with ckpt inhibitors in other cancers. usually controllable. #mmsm
1
0
2
@CohenAd_MMdoc
Adam D Cohen, MD
@CohenAd_MMdoc
10 years
May be beneficial to combine CAR T cells with autoSCT http://t.co/5NPTNEToTV #mmsm
0
1
2
@CohenAd_MMdoc
Adam D Cohen, MD
@CohenAd_MMdoc
10 years
@MyelomaTeacher That's the hope but too early to know if will work in myeloma and for how long. #mmsm
0
1
2
@CohenAd_MMdoc
Adam D Cohen, MD
@CohenAd_MMdoc
10 years
#mmsm Multiple CAR targets in MM: CD19, CD38, CS1, BCMA, CD138, kappa. Recent review http://t.co/PQAq6QKTuM
0
5
7
@CohenAd_MMdoc
Adam D Cohen, MD
@CohenAd_MMdoc
10 years
@MyelomaTeacher yes, takes patient's own T cells, adds receptor to target MM cell, then infuses back to patient. http://t.co/0cVTp8ub8K
0
0
1
@CohenAd_MMdoc
Adam D Cohen, MD
@CohenAd_MMdoc
10 years
@mtmdphd Makes sense, since relatively low toxicity. Currently being tested in trials. #mmsm
0
0
1
@CohenAd_MMdoc
Adam D Cohen, MD
@CohenAd_MMdoc
10 years
@myelomacinderel that's the idea that you may get better memory immune response, but not proven yet in humans #mmsm
1
1
2
@CohenAd_MMdoc
Adam D Cohen, MD
@CohenAd_MMdoc
10 years
@MyelomaTeacher #mmsm ckpt inhibitor here means removing a brake on the immune system. Yes, mAb target receptors on outside of cell
0
0
1
@CohenAd_MMdoc
Adam D Cohen, MD
@CohenAd_MMdoc
10 years
#mmsm Urelumab: Anti-CD137 agonist Ab – provides costimulatory signal to enhance T and NK cell proliferation, persistence, function
1
0
1
@CohenAd_MMdoc
Adam D Cohen, MD
@CohenAd_MMdoc
10 years
#mmsm Nivolumab (antiPD1) with no single-agent responses but prolonged SD in subset of rel/ref MM http://t.co/vknllaCHt7
0
0
2